MCID: ANL008
MIFTS: 24

Anal Carcinoma in Situ

Categories: Cancer diseases

Aliases & Classifications for Anal Carcinoma in Situ

MalaCards integrated aliases for Anal Carcinoma in Situ:

Name: Anal Carcinoma in Situ 12 15
Carcinoma in Situ of Anal Canal 12 74
Carcinoma in Situ of Anus 12 74
Anal Intraepithelial Neoplasia Grade Iii 12
Anal Carcinoma Stage 0 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9087
ICD9CM 36 230.6
SNOMED-CT 69 20365006 92537005

Summaries for Anal Carcinoma in Situ

Disease Ontology : 12 An in situ carcinoma that is located in the anus.

MalaCards based summary : Anal Carcinoma in Situ, also known as carcinoma in situ of anal canal, is related to in situ carcinoma and cervical cancer. An important gene associated with Anal Carcinoma in Situ is SERPINB3 (Serpin Family B Member 3), and among its related pathways/superpathways is Transcriptional misregulation in cancer. The drugs Fentanyl and Pancreatic Polypeptide have been mentioned in the context of this disorder. Affiliated tissues include skin, liver and the anus, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Anal Carcinoma in Situ

Diseases related to Anal Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 in situ carcinoma 9.9
2 cervical cancer 9.7 MYC SERPINB3
3 ewing sarcoma 9.5 FUS MYC

Symptoms & Phenotypes for Anal Carcinoma in Situ

GenomeRNAi Phenotypes related to Anal Carcinoma in Situ according to GeneCards Suite gene sharing:

27 (show all 21)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.8 FUS
2 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.8 FUS
3 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.8 MYC
4 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.8 FUS
5 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.8 FUS
6 Increased shRNA abundance (Z-score > 2) GR00366-A-24 9.8 MYC
7 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.8 MYC
8 Increased shRNA abundance (Z-score > 2) GR00366-A-3 9.8 FUS
9 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.8 FUS
10 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.8 FUS
11 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.8 FUS MYC
12 Increased shRNA abundance (Z-score > 2) GR00366-A-77 9.8 FUS
13 Increased shRNA abundance (Z-score > 2) GR00366-A-78 9.8 FUS
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-112 9.76 FUS
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-144 9.76 MYC
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-160 9.76 MYC
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.76 MYC
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-26 9.76 MYC
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.76 FUS
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 9.76 FUS MYC
21 shRNA abundance <= 50% GR00343-S 8.8 FUS MYC SERPINB3

Drugs & Therapeutics for Anal Carcinoma in Situ

Drugs for Anal Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 17)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
3 Cola Phase 3
4 Central Nervous System Depressants Phase 3
5 Peripheral Nervous System Agents Phase 3
6 Analgesics, Opioid Phase 3
7 Anesthetics Phase 3
8 Anesthetics, Intravenous Phase 3
9 Narcotics Phase 3
10 Adjuvants, Anesthesia Phase 3
11 Analgesics Phase 3
12 Liver Extracts Phase 3
13 Anesthetics, General Phase 3
14
Formaldehyde Approved, Vet_approved Phase 2 50-00-0 712
15
Cidofovir Approved Phase 2 113852-37-2 60613
16 Anti-Infective Agents Phase 2
17 Antiviral Agents Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus Completed NCT00550589 Phase 2 cidofovir
3 A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRXâ„¢ Anorectal Wand Recruiting NCT03302858 Phase 2

Search NIH Clinical Center for Anal Carcinoma in Situ

Genetic Tests for Anal Carcinoma in Situ

Anatomical Context for Anal Carcinoma in Situ

MalaCards organs/tissues related to Anal Carcinoma in Situ:

42
Skin, Liver

The Foundational Model of Anatomy Ontology organs/tissues related to Anal Carcinoma in Situ:

20
The Anus

Publications for Anal Carcinoma in Situ

Articles related to Anal Carcinoma in Situ:

# Title Authors Year
1
Risk of anal carcinoma in situ in relation to human papillomavirus type 16 variants. ( 9731493 )
1998

Variations for Anal Carcinoma in Situ

Expression for Anal Carcinoma in Situ

Search GEO for disease gene expression data for Anal Carcinoma in Situ.

Pathways for Anal Carcinoma in Situ

Pathways related to Anal Carcinoma in Situ according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.89 FUS MYC

GO Terms for Anal Carcinoma in Situ

Biological processes related to Anal Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 8.62 MYC SERPINB3

Sources for Anal Carcinoma in Situ

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....